A Study of the Jovi Patch, Powered by Signal Relief, for the Improvement of General Menstrual Discomfort
This pilot study is testing whether a thin, flexible, drug-free patch called the Jovi Patch (powered by Signal Relief) can help reduce general menstrual discomfort (pain and related symptoms during periods).
The patch contains no medication, wires, or batteries. It uses special micro-metal particles that are thought to interact with the body's natural electrical signals related to pain. Researchers will compare an active version of the patch to a look-alike sham (inactive) patch.
About 50 pre-menopausal women ages 18-50 who have menstrual discomfort (pain score greater than 4 on a 0-10 scale) will be randomly assigned to one of two groups:
Active patch group (larger group) Sham patch group
Participants will wear their assigned patch during six menstrual cycles (starting the day before their period begins and continuing through the week of flow). After three cycles, women in the sham group will switch to the active patch for the remaining three cycles so researchers can also look at the effects of switching.
The main question is whether more women using the active patch achieve at least a 30% reduction in their pain scores compared with those using the sham patch. The study will also track changes in how much menstrual symptoms interfere with daily life, use of pain medications, and any side effects (such as skin irritation).
Participation lasts through six menstrual cycles. The overall study is expected to take up to 12 months.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a pilot, randomized, double-blind, sham-controlled study with a crossover component evaluating the Jovi Patch (powered by Signal Relief) for the management of primary dysmenorrhea-related symptoms (general menstrual discomfort).
Menstrual discomfort is common and can significantly affect quality of life. It is largely driven by prostaglandin-mediated uterine hyper-contractility, leading to pain and associated symptoms such as low back pain, nausea, fatigue, and interference with daily activities. First-line treatments are typically nonsteroidal anti-inflammatory drugs (NSAIDs); non-drug options remain limited.
The Jovi Patch is a thin, flexible, non-invasive, drug-free device that contains no wires or batteries. It incorporates conductive particle arrays (micro-metals) designed to interact with the body's electrical signals associated with pain. The proposed mechanism is that the patch provides a preferential pathway for pain-related electrical signals, thereby reducing the intensity of signals reaching the brain. The patch is applied externally to the lower abdomen and/or lower back and is intended to be worn continuously during the menstrual period (except when showering or swimming).
Approximately 50 pre-menopausal women will be randomized in a 1:3 ratio (active:sham) to wear either the active Jovi Patch or a matching sham patch during six consecutive menstrual cycles. After the first three cycles, participants originally assigned to the sham patch will cross over to the active patch for the remaining three cycles. This design allows evaluation of both parallel-group and within-subject effects.
This pilot study is not powered for definitive efficacy conclusions. It is intended to generate preliminary safety and efficacy data to inform future research and product development. The study is being conducted at Redeemer Health in Meadowbrook, Pennsylvania. Participation lasts through six menstrual cycles; the overall study is expected to take up to 12 months.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Ashley Trymbiski
- Número de telefone: 4452008090
- E-mail: atrymbiski@gmail.com
Locais de estudo
-
-
Pennsylvania
-
Meadowbrook, Pennsylvania, Estados Unidos, 19046
- Recrutamento
- Redeemer Health
-
Investigador principal:
- Stacy Krisher, MD
-
Contato:
- Ashley Trymbiski
- Número de telefone: 4452008090
- E-mail: atrymbiski@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Pre-menopausal female subjects aged 18 -50 years.
- Currently seeking treatment for general menstrual discomfort
- NPRS scale score > 4 at baseline.
- Able and willing to provide informed consent in English without the assistance of an interpreter.
Exclusion Criteria:
- Receiving other investigational agents or on another clinical trial.
- Subject has implantable pain device, pacemaker, defibrillator, or other neuromodulation implantable device.
- Known to be pregnant, or plan to become pregnant in the next 6 months
- Current Jovi/Signal Relief users
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Active Jovi Patch
Participants receive the active Jovi Patch (powered by Signal Relief), a non-invasive, drug-free flexible wellness patch containing conductive particle arrays.
The patch is worn during six consecutive menstrual cycles (or three cycles if crossing over from sham).
|
Non-invasive, drug-free flexible wellness patch containing conductive particle arrays
|
|
Comparador Falso: Sham Patch
Participants receive a matching inactive (sham) patch that is identical in appearance to the active Jovi Patch but does not contain the conductive particle arrays.
After three cycles, these participants cross over to the active Jovi Patch for the remaining three cycles.
|
Matching inactive (sham) patch that is identical in appearance to the active Jovi Patch but does not contain the conductive particle arrays
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of Participants Achieving at Least 30% Change in NPRS Score
Prazo: Baseline to end of treatment (after 6 menstrual cycles)
|
Proportion of participants who achieve at least a 30% change in their Numeric Pain Rating Scale (NPRS) score (0 = no pain, 10 = worst imaginable pain) from baseline to the end of treatment.
|
Baseline to end of treatment (after 6 menstrual cycles)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- Jovi-01-25
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .